Amgen expands oncology portfolio with UK biotech and Oxford spinout acquisitions
Amgen has announced a deal to acquire a UK-based cancer biotechnology company for up to $840 million, marking a significant expansion in its oncology portfolio.
Tag
Cancer Biotech
All articles tagged with #cancer biotech
Nuvalent Raises $300M in Public Stock Offering
Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.